Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and orexin-2 receptors, in selected populations of MCI and mild-to-moderate AD patients with insomnia complaints.
Epistemonikos ID: a06e58bfce3adcdd63d6ed57072a996e0c3ee76d
First added on: May 15, 2024